全國服務咨詢熱線：
18438616290
18438616290
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 152121-47-6 |
|---|---|---|---|
| 分子式 | C21H16FN3OS | 純度 | ＞98% |
| 分子量 | 377.44 | 貨號 | abs810002 |
| 規格 | 5mg;10mg;100mg | 供貨周期 | 現貨 |
| 主要用途 | - | 應用領域 | 化工,生物產業,農林牧漁,制藥/生物制藥,綜合 |
| 產品描述 | |
| 描述 | SB 203580是一種p38 MAPK抑制劑，在THP-1細胞中IC50為0.3-0.5μM，對SAPK3(106T)和SAPK4(106T)選擇性低10倍，且阻斷PKB磷酸化，IC50為3-5μM。SB203580是第一個被報道的p38抑制劑。 |
| 純度 | ＞98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | Adezmapimod；RWJ 64809 |
| 外觀 | white to off-white powder |
| 可溶性/溶解性 | DMSO：43 mg/mL (113.92 mM) |
| 生物活性 | |
| 靶點 | p38 MAPK；PKB |
| In vitro(體外研究) | SB 203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 μm range. SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas inhibits total SAPK/JNK activity with an IC50 of 3–10 μM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells. |
| In vivo(體內研究) | SB203580 protects pig myocardium against ischemic injury in an in vivo model. SB203580 is effective to prevent and treat the disease in MRL/lpr mice model of Systemic lupus erythematosus (SLE). |
| 研究領域 | |
| 研究領域 | ImmunologyInnate ImmunityTLR Signaling NeuroscienceDevelopment NeuroscienceProcesses Signal TransductionProtein PhosphorylationSer / Thr KinasesMAPK Pathway Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
地址：上海市浦東新區新浩路58號申江科創園18棟
郵箱：lanwu@univ-bio.com
傳真：